BXD recombinant inbred mice represent a novel T cell-mediated immune response tumor model

被引:22
作者
Grizzle, WE
Mountz, JD
Yang, PA
Xu, X
Sun, S
Van Zant, GE
Williams, RW
Hsu, HC
Zhang, HG
机构
[1] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
[2] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA
[3] Vet Adm Med Ctr, Birmingham, AL USA
[4] Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Div Hematol Oncol, Lexington, KY 40536 USA
[5] Univ Tennessee, Ctr Neurosci, Memphis, TN USA
[6] Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN USA
关键词
T cell; breast cancer; tumor susceptibility; BXD mice;
D O I
10.1002/ijc.10606
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To develop a better animal model for studying the effects of the host environment in neoplasia, we injected various genetically well-characterized H-2(d) RI strains of BXD mice with syngeneic breast cancer cells (TS/A) and monitored the growth of tumors over time. There was a marked difference in the growth of the implanted breast cancer cells among the 14 BXD RI strains, with 4 patterns of tumor development being observed: in type I, the implanted tumor cells grew rapidly in the first 2 weeks, necrosis of the tumors was observed and metastases to the intestinal lymph nodes and pancreas was observed, causing death; in type II, the implanted tumor cells grew slowly and attained a size after day 50 that required killing the animal, with tumor necrosis being rare and metastases absent; in type III, the implanted tumor cells grew initially but underwent a slow decline after 4 weeks; and in type IV, the implanted tumor cells failed to develop. Apoptosis of the implanted tumor cells was responsible for the regression of tumor nodules. The T-cell immune response minimized tumor development in types III and IV since T-cell depletion of the BXD III mice resulted in aggressively growing tumors in these strains. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:270 / 279
页数:10
相关论文
共 52 条
[1]  
Alpaugh ML, 1999, CANCER RES, V59, P5079
[2]   Construction of a recombinant adenovirus vector encoding Fas ligand with a CRE/loxp inducible system [J].
Bilbao, G ;
Zhang, H ;
Contreras, JL ;
Zhou, T ;
Feng, M ;
Saito, I ;
Mountz, JD ;
Curiel, DT .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :792-793
[3]  
Borovansky J, 1997, NEOPLASMA, V44, P277
[4]  
Céfai D, 2001, INT J CANCER, V91, P529, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1074>3.0.CO
[5]  
2-O
[6]   Human breast cancer cell line xenografts as models of breast cancer - The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines [J].
Clarke, R .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 39 (01) :69-86
[7]   Further characterization and high-resolution mapping of quantitative trait loci for ethanol-induced locomotor activity [J].
Demarest, K ;
Koyner, J ;
McCaughran, J ;
Cipp, L ;
Hitzemann, R .
BEHAVIOR GENETICS, 2001, 31 (01) :79-91
[8]   GENETIC-LINKAGE OF THYMIC T-CELL PROLIFERATIVE UNRESPONSIVENESS TO MOUSE CHROMOSOME-11 IN NOD MICE - A POSSIBLE ROLE FOR CHEMOKINE GENES [J].
GILL, BM ;
JARAMILLO, A ;
MA, LL ;
LAUPLAND, KB ;
DELOVITCH, TL .
DIABETES, 1995, 44 (06) :614-619
[9]   Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients [J].
Glover, MT ;
Deeks, JJ ;
Raftery, MJ ;
Cunningham, J ;
Leigh, IM .
LANCET, 1997, 349 (9049) :398-398
[10]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366